Researchers at the National Institute of Neurological Disorders and Stroke (NINDS) are seeking patients with multiple sclerosis (MS) for an experimental treatment trial. The study will test an experimental drug's ability to reduce disease activity as seen on magnetic resonance imaging (MRI) scans. Testing of this drug will be carried out in compliance with FDA guidelines.
Eligible patients must be 18 to 65 years old, have relapsing/remitting or secondary progressive MS, and be taking Avonex or Betaseron for at least a 6-month period and continuing to have exacerbations. The studies will be conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, physicians should send a referral letter and a copy of the patient's recent medical records to Joan Eaton, RN, CRNP, Neuroimmunology Branch, NINDS, NIH, Building 10, Room 5B16, 10 Center Drive MSC 1430, Bethesda, MD 20892-1430; telephone: (301) 496-0064; fax: (301) 402-0373; email: email@example.com.